Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Ocugen, Inc. (OCGN : NSDQ)
 
 • Company Description   
Ocugen Inc. is a clinical stage biopharmaceutical company. It is focused on discovering, developing and commercializing therapies which address rare and underserved eye diseases. The company's product pipeline consists of OCU400, OCU300, OCU100 and OCU200 which are in clinical stage. Ocugen Inc., formerly known as Histogenics Cp, is based in Malvern, Pennsylvania.

Number of Employees: 95

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.96 Daily Weekly Monthly
20 Day Moving Average: 8,149,243 shares
Shares Outstanding: 292.03 (millions)
Market Capitalization: $279.47 (millions)
Beta: 4.18
52 Week High: $1.98
52 Week Low: $0.52
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 0.43% -5.01%
12 Week 42.92% 19.90%
Year To Date 18.88% 11.35%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
11 GREAT VALLEY PARKWAY
-
MALVERN,PA 19355
USA
ph: 484-328-4701
fax: 781-547-4452
ir@ocugen.com http://ocugen.com
 
 • General Corporate Information   
Officers
Shankar Musunuri - Chairman; Chief Executive Officer & Co-Founder
Ramesh Ramachandran - Chief Accounting Officer
Junge Zhang - Director
Uday Kompella - Director
Kirsten Castillo - Director

Peer Information
Ocugen, Inc. (CORR.)
Ocugen, Inc. (RSPI)
Ocugen, Inc. (CGXP)
Ocugen, Inc. (BGEN)
Ocugen, Inc. (GTBP)
Ocugen, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 67577C105
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/14/25
Share - Related Items
Shares Outstanding: 292.03
Most Recent Split Date: 9.00 (0.02:1)
Beta: 4.18
Market Capitalization: $279.47 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.05 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.23 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/14/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 17.56
Price/Cash Flow: -
Price / Sales: 61.80
EPS Growth
vs. Year Ago Period: 0.00%
vs. Previous Quarter: 0.00%
Sales Growth
vs. Year Ago Period: 46.06%
vs. Previous Quarter: 93.85%
ROE
06/30/25 - -
03/31/25 - -223.00
12/31/24 - -184.09
ROA
06/30/25 - -
03/31/25 - -92.20
12/31/24 - -91.34
Current Ratio
06/30/25 - -
03/31/25 - 2.60
12/31/24 - 2.86
Quick Ratio
06/30/25 - -
03/31/25 - 2.60
12/31/24 - 2.86
Operating Margin
06/30/25 - -
03/31/25 - -1,271.12
12/31/24 - -1,333.02
Net Margin
06/30/25 - -
03/31/25 - -1,271.12
12/31/24 - -1,333.02
Pre-Tax Margin
06/30/25 - -
03/31/25 - -1,271.12
12/31/24 - -1,333.02
Book Value
06/30/25 - -
03/31/25 - 0.05
12/31/24 - 0.10
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 1.74
12/31/24 - 0.92
Debt-to-Capital
06/30/25 - -
03/31/25 - 63.49
12/31/24 - 47.99
 

Powered by Zacks Investment Research ©